AI Article Synopsis
- The study examined the urinary excretion of steroid metabolites in 60 gastric cancer patients, revealing a significant decrease in androgen activity, particularly in 17-ketosteroids.
- The findings indicated that as the disease progressed, the ratio of androsterone to etiocholanolone fell below 1 for most patients, suggesting androgen insufficiency.
- An increase in glucocorticoid function was noted in stage II-III patients but decreased in stage IV, indicating a complex relationship between androgens and glucocorticoids in gastric cancer's impact on metabolism.
Article Abstract
The urinary excretion of andro- and glucocorticoidogenesis metabolites was studied in 60 patients with gastric cancer (stages II-III and IV). The androgenous activity showed a significant decrease that was manifested in a reduced excretion of 17-ketosteroids (17-KS) and their androgenicity index (AI). With advance of the disease stage androsterone/ethiocholanolon ratio reduced and became less than 1 in most patients. In patients with stage II-III gastric cancer there occurred a significant increase of the glucocorticoid function of the adrenals and a decrease in patients with stage IV cancer. Comparison with the androgenous activity revealed both an absolute and a relative androgenic insufficiency in patients with gastric cancer. It is suggested that reduced production of androgens effects favourably the catabolic manifestation of the effect of glucocorticoids. Drug-stimulated increase of the production of androgens in the body of patients with gastric cancer is desired.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!